The major purpose for the design of 6MW3211 is to obtain therapeutic benefit by selectively blocking the interaction of CD47 and SIRPα on PD-L1 and CD47 double positive tumor cells, but not binding to CD47 expressing on RBCs and other normal cells. Here, CD47 is linked to neoplasm.